NCT01663766 - Phase I Study of Milatuzumab for Graft Versus Host Disease | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

March 31, 2015

Study Completion Date

March 31, 2015

Conditions

GVHD (Acute or Chronic)Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)Myelodysplastic SyndromeChronic Myelogenous Leukemia (CML)Multiple Myeloma (MM)Non-Hodgekin Lymphoma (NHL-both Follicular & Diffuse Large Cell)Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia (CLL or SLL)

Interventions

DRUG

milatuzumab

Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus